Experimental drug could target IDH1 mutant gliomas, preclinical study indicates

Written by Alice Weatherston

Findings recently published in Cancer Cell have indicated that experimental cell metabolism altering drugs may be effective in the prevention of tumor growth in mice with mutations in the IDH1 gene. The findings could be relevant for up to a third of gliomas that are affected by this mutation. The study, which was led by researchers at NYU Langone Medical Center (NY, USA), examined human cancer cells carrying the IDH1 mutations both in vitro and in vivo. Analysis of metabolic components highlighted that nicotinamide adenine dinucleotide (NAD) levels were unusually low in IDH1 mutant tumors. When NAD levels were further...

To view this content, please register now for access

It's completely free